Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (546)	3/7/2005 10:08:55 PM
From: DewDiligence_on_SI	of 946

>>I bring up economics because paclitaxel is generic. Although CTIC did not really discuss pricing that I'm aware of, I think it is a safe assumption that Xyotax was going to be priced competitively against branded products rather than competitively against generics.<< It’s refreshing to see someone address the pricing issue. There have been so many posts about whether Xyotax is still approvable and hardly any about whether it will still be able to be a commercial success.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next